Rhinitis/rhinorrhea (intranasal products):
Indications for: NASONEX
Treatment of seasonal and perennial allergic rhinitis symptoms in patients ≥2yrs of age. Prophylaxis of seasonal allergic rhinitis symptoms in patients ≥12yrs of age. Nasal polyps.
Allergic rhinitis: 2 sprays in each nostril once daily; prophylaxis: begin 2–4 weeks prior to anticipated start of pollen season. Nasal polyps: ≥18yrs: 2 sprays in each nostril 1–2 times daily.
Allergic rhinitis: <2yrs: not established. 2–11yrs: 1 spray in each nostril once daily. Nasal polyps: <18yrs: not established.
Maintain regular regimen. Immunosuppression. Respiratory tract tuberculosis. Infections (eg, ocular herpes simplex). If exposed to measles or chickenpox, consider anti-infective prophylactic therapy. Monitor for growth suppression in children. Monitor for hypercorticism and adrenal suppression (if occur discontinue gradually), and candida infection or other nasal mucosal changes. Glaucoma and/or cataracts. Discontinue if nasopharyngeal candida infection occurs. Avoid eyes. Pregnancy. Nursing mothers.
Caution when concomitant ketoconazole (long-term) and other strong CYP3A4 inhibitors (eg, ritonavir, cobicistat-containing products, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin); monitor.
Headache, viral infection, pharyngitis, epistaxis, cough, upper respiratory tract infection, dysmenorrhea, pain, sinusitis; reduced growth velocity in children, nasal ulcers.
Generic Drug Availability:
Spray—17g (120 sprays)